| 0.6601 -0.144 (-17.95%) | 11-20 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.93 |
1-year : | 1.07 |
| Resists | First : | 0.79 |
Second : | 0.92 |
| Pivot price | 0.82 |
|||
| Supports | First : | 0.6 |
Second : | 0.49 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.83 |
| MA(100) : | 0.81 |
MA(250) : | 1.28 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.4 |
D(3) : | 60.4 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 4.55 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACER ] has closed below the lower bollinger band by 31.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ACER ] is to continue within current trading range. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.86 | 0.86 - 0.87 |
| Low: | 0.77 - 0.78 | 0.78 - 0.78 |
| Close: | 0.79 - 0.81 | 0.81 - 0.82 |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Mon, 20 Nov 2023
Zevra Therapeutics Acquires Acer Therapeutics - Contract Pharma
Fri, 15 Sep 2023
Zevra adds Edsivo for vEDS to its rare disease portfolio in new deal - Ehlers-Danlos News
Fri, 01 Sep 2023
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up - Yahoo Finance
Thu, 31 Aug 2023
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding - GlobeNewswire
Tue, 15 Aug 2023
Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 29.9 (%) |
| Shares Short | 494 (K) |
| Shares Short P.Month | 898 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | -0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|